UY37725A - Derivados de quinazolina-piridina para el tratamiento de trastornos relacionados con el cáncer - Google Patents

Derivados de quinazolina-piridina para el tratamiento de trastornos relacionados con el cáncer

Info

Publication number
UY37725A
UY37725A UY0001037725A UY37725A UY37725A UY 37725 A UY37725 A UY 37725A UY 0001037725 A UY0001037725 A UY 0001037725A UY 37725 A UY37725 A UY 37725A UY 37725 A UY37725 A UY 37725A
Authority
UY
Uruguay
Prior art keywords
cancer
treatment
quinazoline
related disorders
pyridine derivatives
Prior art date
Application number
UY0001037725A
Other languages
English (en)
Inventor
Reddy Leleti Manmohan
Thomas-Tran Rhiannon
Harding Miles Dillon
Patrick Powers Jay
Reid Rosen Brandon
Ul Sharif Ehesan
Original Assignee
Arcus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcus Biosciences Inc filed Critical Arcus Biosciences Inc
Publication of UY37725A publication Critical patent/UY37725A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente se describen compuestos que inhiben al menos uno de los receptores de adenosina A2A y A2B y las composiciones que contienen el compuesto y los métodos para sintetizar el compuesto. Asimismo se describen el uso de dichos compuestos y composiciones para el tratamiento de una amplia gama de enfermedades, trastornos y condiciones, incluyendo trastornos relacionados con el cáncer y el sistema inmunitario que están mediados, al menos parcialmente, por el receptor de adenosina A2A y/o por el receptor de adenosina A2B.
UY0001037725A 2017-05-05 2018-05-04 Derivados de quinazolina-piridina para el tratamiento de trastornos relacionados con el cáncer UY37725A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762502391P 2017-05-05 2017-05-05
US201862624273P 2018-01-31 2018-01-31

Publications (1)

Publication Number Publication Date
UY37725A true UY37725A (es) 2018-10-31

Family

ID=64016681

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037725A UY37725A (es) 2017-05-05 2018-05-04 Derivados de quinazolina-piridina para el tratamiento de trastornos relacionados con el cáncer

Country Status (9)

Country Link
US (1) US11045472B2 (es)
EP (1) EP3618829B1 (es)
JP (1) JP7295034B2 (es)
CN (1) CN110612100B (es)
ES (1) ES2953349T3 (es)
PL (1) PL3618829T3 (es)
TW (1) TWI789393B (es)
UY (1) UY37725A (es)
WO (1) WO2018204661A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2951809T3 (es) * 2017-05-17 2023-10-25 Arcus Biosciences Inc Derivados de quinazolina-pirazol para el tratamiento de trastornos relacionados con el cáncer
CN109293586A (zh) * 2018-11-22 2019-02-01 云南师范大学 一种在氨水中微波条件下卤代苯甲酸合成喹唑啉酮化合物的方法
WO2020146563A1 (en) * 2019-01-10 2020-07-16 Dana-Farber Cancer Institute, Inc. Modulating biomarkers such as spp to increase tumor immunity and improve the efficacy of cancer immunotherapy
IL295569A (en) 2020-03-19 2022-10-01 Arcus Biosciences Inc Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
PE20231078A1 (es) 2020-06-02 2023-07-17 Arcus Biosciences Inc Anticuerpos anti-tigit
US11649261B2 (en) 2020-06-17 2023-05-16 Arcus Biosciences, Inc. Crystalline forms of a CD73 inhibitor and uses thereof
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
EP4341262A1 (en) 2021-05-21 2024-03-27 Arcus Biosciences, Inc. Axl inhibitor compounds
WO2022246177A1 (en) 2021-05-21 2022-11-24 Arcus Biosciences, Inc. Axl compounds
EP4423069A1 (en) 2021-10-29 2024-09-04 Arcus Biosciences, Inc. Inhibitors of hif-2alpha and methods of use thereof
WO2023215719A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
US20240124490A1 (en) 2022-07-15 2024-04-18 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en) 2022-07-20 2024-01-25 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024081385A1 (en) 2022-10-14 2024-04-18 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
US20240180947A1 (en) 2022-10-20 2024-06-06 Arcus Biosciences, Inc. Lyophilized formulations of cd73 compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1397364T3 (da) * 2001-05-24 2007-11-26 Lilly Co Eli Hidtil ukendte pyrrolderivater som farmaceutiske midler
TWI330183B (es) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
ES2311759T3 (es) * 2003-05-06 2009-02-16 Cv Therapeutics, Inc. Derivados de xantina como antagonistas del receptor a2b de adenosina.
BRPI0417478A (pt) * 2003-12-15 2007-05-08 Almirall Prodesfarma Ag 2,6-bis-heteroaril-4-aminopirimidinas como antagonistas de receptor de adenosina
TW200813056A (en) * 2006-06-29 2008-03-16 King Pharmaceuticals Res Dev Inc Adenosine A2B receptor antagonists
TWI473614B (zh) * 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
WO2010033906A2 (en) * 2008-09-19 2010-03-25 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
WO2016126570A1 (en) * 2015-02-06 2016-08-11 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as a2a antagonist

Also Published As

Publication number Publication date
US11045472B2 (en) 2021-06-29
CN110612100B (zh) 2023-04-14
TW201843150A (zh) 2018-12-16
EP3618829C0 (en) 2023-06-07
EP3618829A1 (en) 2020-03-11
TWI789393B (zh) 2023-01-11
CN110612100A (zh) 2019-12-24
JP2020518627A (ja) 2020-06-25
US20200069689A1 (en) 2020-03-05
PL3618829T3 (pl) 2023-11-20
EP3618829B1 (en) 2023-06-07
JP7295034B2 (ja) 2023-06-20
EP3618829A4 (en) 2021-01-06
WO2018204661A1 (en) 2018-11-08
ES2953349T3 (es) 2023-11-10

Similar Documents

Publication Publication Date Title
UY37725A (es) Derivados de quinazolina-piridina para el tratamiento de trastornos relacionados con el cáncer
UY37574A (es) Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer
CO2017008403A2 (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
ECSP20060827A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
ECSP20079887A (es) Derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores pd-l1
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
CO2018013105A2 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
GT201600215A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
BR112018015419A2 (pt) degradantes seletivos de receptor de estrogênio e os usos dos mesmos
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CL2018003444A1 (es) Derivados de adenosina para uso en el tratamiento del cancer.
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
UY36003A (es) Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina.
EA202192093A1 (ru) Пиразолопиридины и триазолопиридины в качестве ингибиторов a2а/a2b
CU24519B1 (es) Derivados de aminotiazol útiles como agentes antivíricos
CL2018003121A1 (es) Inhibidores del potenciador del homólogo zeste 2.
CL2017000152A1 (es) Derivados de isoindolinona
CR20160558A (es) Compuesto de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer
CU20170083A7 (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos útiles para el tratamiento de enfermedades asociadas al dolor, y para el tratamiento o profilaxis de los síndromes del dolor, de la endometriosis, la adenomiosis y el cáncer
CL2017000644A1 (es) Compuestos esteroides c-20, composiciones y usos de estos para tratar lesiones cerebrales traumáticas (tbi), incluidas concusiones.
EA202190204A1 (ru) Производные конденсированных пиразинов как ингибиторы a2a/a2b

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20240627